All In Biotech

Drug Trial Radar · NCT07362264

A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors

An Open, Multicenter, Phase I Clinical Study on the Safety, Efficacy, and Pharmacokinetics of SH006 Injection Combination in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 1, 2025

Primary completion

Dec 30, 2026

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of the combination therapy of SH006 injection in patients with advanced solid tumors

Conditions

  • Liver Cancer

Interventions

  • SH006Drug

    The dosage of SH006 is 15 mg/kg Q3W or 30 mg/kg Q3W, with a treatment cycle of 21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Days 1-21
  2. Recommended Phase 2 Dose (RP2D)Time frame: up to 21 days
  3. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Within 90 days from the first administration to the last administration of the SH006 combination therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Tianyinshan Hospital

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.